
Trio, including former Novartis exec, accused of bribery to the tune of over HK$1.5 million
pharmafile | November 28, 2017 | News story | Manufacturing and Production, Sales and Marketing | Novartis, bribery, illegal
A trio, including a former Senior Medical Representative at Novartis, have been charged over allegedly conspiring to offer and accept bribes of more than HK$1.5 million (US$192,000) in relation to the sale of pharmaceutical products, according to Hong Kong’s Independent Commission Against Corruption.
A joint charge alleges that, between January 2014 and April 2015, 42-year-old Gavin Wong Chun-yin, formerly of Novartis, unlawfully accepted a total of HK$946,750 from 52-year-old Wong Chung-sum, Operator of Hygience Medicine Limited (HML), in exchange for supplying Novartis’ drugs to HML.
A second charge accuses Tsoi Lai-ngan, 58 of Man Hong Dispensary (MHD), of unlawfully giving HK$563,000 to Gavin Wong over a 10-year period from 2005 to 2015, again for supplying Novartis drugs to MHD.
The three accused will appear at the Eastern Magistracy on 30 November.
Matt Fellows
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …






